Featured

This Week in HIV Research: Additional Nuance on Pregnancy and Antiretrovirals

Switching HIV treatment regimens during the first trimester; drivers of viral breakthrough during pregnancy; HIV’s effect on liver risk after hepatitis C treatment; hepatic steatosis among young people with HIV.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Exorcizing Our PrEP Demons

Experts push for normalization of PrEP; U.S. HIV transmission rates across the care continuum; sociodemographic disadvantage and HIV drug resistance; real-world success of integrase inhibitors for treatment-experienced people.

By Myles Helfand

This Week in HIV Research: Prevention and Treatment in the Real World

Impact of intimate partner violence on PrEP attitudes among women; evolution of first-line HIV treatment failure rates; cumulative low-level viremia and virologic failure risk; HIV drug levels in breast milk versus plasma.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: How Low (an Atripla Dose) Can You Go?

Atripla may be just as effective when taken every other day; poor antiretroviral prescription fill rates after hospitalization; U.S. progress against UNAIDS targets; hepatitis C transmission clustering in France.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: The Clinical Impacts of HIV Stigma

Internalized HIV stigma, depression, and adherence in women; what “internalized HIV stigma” actually means; tenofovir-containing gel and genital herpes prevention; the neurocognitive effects of cerebrospinal HIV escape.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: The Science of Risk

Traditional factors vs. HIV-specific factors in non-communicable complications; frailty and fracture risk among women; lipid measurements and coronary risks; new data on efavirenz and birth defects.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Rethinking PrEP Guidelines

Alternate PrEP guideline recommendations; partner notification and onward HIV transmission; shifting causes of death among HIV/HCV-coinfected people; correlates of lower adherence among people on methadone maintenance.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Don't Assume PrEP Use Increases STI Rates

New for the week ending March 15: Study of young black MSM finds no link between PrEP uptake and STI incidence; HIV risk scores and PrEP usage; impact of youth-tailored HIV services; long-acting antiretroviral interest among younger people with HIV.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: The Power of 10,000 Steps

Cardiorespiratory fitness and inflammation among sedentary people with HIV; helping patients increase physical activity; transwomen and metabolic syndrome; failed treatment of precancerous cervical lesions.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Check Your Frailty

The link between frailty and chronic disease development; Atripla’s long-term efficacy; the dangers of restrictive eligibility criteria for hepatitis C treatment; nicotine metabolism rates in people living with HIV.

By Barbara Jungwirth and Myles Helfand